169 related articles for article (PubMed ID: 8941003)
1. Breast carcinoma detection with a combination of radiolabeled monoclonal antibodies. Promising results from immunohistochemistry studies.
Mangili F; Sassi I; Di Rocco M; Leone BE; Garancini P; Santambrogio G
Cancer; 1996 Dec; 78(11):2334-9. PubMed ID: 8941003
[TBL] [Abstract][Full Text] [Related]
2. Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.
Roselli M; Hitchcock CL; Molinolo A; Milenic DE; Colcher D; Martin EW; Hinkle GH; Schlom J
Anticancer Res; 1995; 15(3):975-84. PubMed ID: 7645989
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases.
Briffod M; Hacène K; Le Doussal V
Mod Pathol; 2000 Aug; 13(8):841-50. PubMed ID: 10955449
[TBL] [Abstract][Full Text] [Related]
5. Expression of E-cadherin and catenins in invasive mammary carcinomas.
Zschiesche W; Schönborn I; Behrens J; Herrenknecht K; Hartveit F; Lilleng P; Birchmeier W
Anticancer Res; 1997; 17(1B):561-7. PubMed ID: 9066580
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
7. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion.
Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Yang Q; Oura S; Sakurai T
Cancer; 1999 Aug; 86(3):439-48. PubMed ID: 10430252
[TBL] [Abstract][Full Text] [Related]
8. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype.
Galietta A; Pizzi C; Pettinato G; Limite G; Sgambato A; Lamberti M; Muraro R; Formisano C; Pensabene M; Bianco AR; Mariani-Costantini R; Contegiacomo A
Oncol Rep; 2002; 9(1):135-40. PubMed ID: 11748471
[TBL] [Abstract][Full Text] [Related]
9. An observation of DNA ploidy, histological grade, and immunoreactivity for tumour-related antigens in primary and metastatic breast carcinoma.
Hitchcock A; Ellis IO; Robertson JF; Gilmour A; Bell J; Elston CW; Blamey RW
J Pathol; 1989 Oct; 159(2):129-34. PubMed ID: 2553906
[TBL] [Abstract][Full Text] [Related]
10. Expression of c-erb B-2 protein and DNA ploidy in breast carcinogenesis.
Schmitt FC; Figueiredo P; Lacerda M
Arch Pathol Lab Med; 1995 Sep; 119(9):815-20. PubMed ID: 7668939
[TBL] [Abstract][Full Text] [Related]
11. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
12. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
13. Biologic characteristics of breast cancer detected by mammography and by palpation in a screening program: a pilot study.
Tweedie E; Tonkin K; Kerkvliet N; Doig GS; Sparrow RK; O'Malley FP
Clin Invest Med; 1997 Oct; 20(5):300-7. PubMed ID: 9336655
[TBL] [Abstract][Full Text] [Related]
14. [The role of epithelial antigens in diagnosis and staging of breast cancer].
Artamonova EV; Tupitsyn NN; Kadagidze ZG; Letiagin VP; Ermilova VD; Ognerubov NA; Panichenko AV; Riazantseva SN
Arkh Patol; 2002; 64(6):13-5. PubMed ID: 12534220
[TBL] [Abstract][Full Text] [Related]
15. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
17. [Immunomorphologic markers in breast cancer].
Volchenko NN; Litvinova LV; Pugachev KK; Shimbireva IB; Kalashnikov VV; Frank GA
Arkh Patol; 1996; 58(1):6-10. PubMed ID: 8929144
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
Honma N; Takubo K; Arai T; Younes M; Kasumi F; Akiyama F; Sakamoto G
APMIS; 2006 Oct; 114(10):712-9. PubMed ID: 17004974
[TBL] [Abstract][Full Text] [Related]
19. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
20. Cysteine proteinase inhibitor cystatin A in breast cancer.
Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
